Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is set to enter into an amended equity joint venture contract concerning Tianjin TSKF Pharmaceutical Co., Ltd., in collaboration with Haleon UK Services Limited and Haleon China Co., Ltd. This strategic move follows a series of announcements regarding the extension of the JV Company’s operating period and a proposed disposal of a 13% equity interest. The Board has affirmed the accuracy and fairness of the information provided in this announcement.
For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.
